What is claimed is:

1. Use of a TNFR25 agonist in the manufacture of a medicament for delaying acute rejection of a transplanted organ or tissue in a subject, wherein the TNFR25 agonist is a TL1A-Ig fusion.

2. The use according to claim 1, wherein the TNFR25 agonist induces proliferation of CD4+FoxP3+ cells in the subject.